Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
June 5, 2008
Trovax for renal cell carcinoma: not much potential
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.
June 4, 2008
Trovax(R) Sanofi-Aventis and Oxford Biomedica: Interesting but.....
Analysis of: Sanofi-Aventis and Oxford Biomedica report encouraging Trovax(R) phase II trial results in Metastatic Renal Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)
June 4, 2008
ASA404 in a phase III trial in lung cancer?? "A crap shoot?"
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor
That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.
June 2, 2008
A New Algorithm Will be Needed to Calculate Market Sharee
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.
June 2, 2008
Lenalidomide is on a surge
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Lenalidomide is recently proving that its potential is not limited to myeloma, but can be used also in other B-cell malignancy settings such as lymphoma and CLL. CLL, in particular, needs light and yet efficacious treatments, particularly in the setting of pretreated (at times heavily) patients.
June 2, 2008
Chinese generics: Low prices bu qulaity reputation will favor India
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...
June 2, 2008
ImClone: One study shot down. The other??
Analysis of: Drug Brings ImClone in From Cold | online.wsj.com
Author: GLG Expert Contributor
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
June 2, 2008
Erbitux (ImClone):1 month and <10% additional survival in lung cancer. Not very impressive!
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study | online.wsj.com
Author: GLG Expert Contributor
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
May 29, 2008
Brain Cancer: Several new treatment strategies with an expected boost from the recent Senator Kennedy diagnosis
Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
For the first time in decades, several drugs like Temodar and Avastin and tumor vaccines ( Avant and others) have shown increased overall survival even in adavnaced and recurrent brain tumors as glioblastoma multiforme. Several agents are in the pipeline, and more Big Pharma involvement is expected...
May 29, 2008
Erbitux did not add to response rates in newly diagnosed in NSCLC
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
The epidermal growth factor antagonist Erbitux did not improve response rates in newly diagnosed patients with advanced non-small cell lung cancer ( NSCLC).  Many patients had hypersensitivity reactions to Cetuximab, which has to be content with its role in colon cancer treatment and to some extent...

Previous Page : 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next111 to 120 of 889

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617